|
|
|
|
TopAbstracts in Fibromyalgia 07/01/2009
TopAbstracts in Fibromyalgia are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 28 days.Over 2000 peer...
|
|
|
The Premenstrual Syndrome and Fibromyalgia-Similarities and Common Features
Clinical Reviews in Allergy and Immunology, 07/02/09 Print Save in My Library Free Abstract Amital D et al.- Patients with PMDD were found to have higher levels of tenderness, higher psychiatric comorbidity, greater level of physical...
|
|
|
Milnacipran: A serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia syndrome
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) that was recently approved by FDA for the management of fibromyalgia syndrome (FMS).In clinical trials, milnacipran has demonstrated efficacy in reducing FMS...
|
|
|
Bill to Fund Neuroendocrine Immune Disorder Center of Excellence in New Jersey OKd by Assembly, Now
Research center would be dedicated to ME/CFS, fibromyalgia, Gulf War Illness, Lyme disease, MCS, and other environmental illnesses.Sat., Jun 27, 2009, via the Co-Cure Listserv: Fantastic news! The New Jersey Assembly has...
|
|
|
June 27, 2009
Research center would be dedicated to ME/CFS, fibromyalgia, Gulf War Illness, Lyme disease, MCS, and other environmental illnesses.Sat., Jun 27, 2009, via the Co-Cure Listserv: Fantastic news! The New Jersey Assembly has...
|
|
|
Quincy Bioscience Enrolling Fibromyalgia and Chronic Fatigue Sufferers in Pilot Study with Prevagen Profession
Chicago - (www.prevagentrials.com) People suffering from the symptoms of Fibromyalgia and Chronic Fatigue are invited to participate in an online pilot study.Quincy Bioscience launched the brain health product Prevagen in September...
|
|
|
Getting personal about personal genetics
I often feel that I have one of the most interesting and gratifying jobs a person can have-reporting on the latest life science breakthroughs and pharmaceutical discoveries, advances that may impact the bottom line of large pharmas and small...
|
|
|
Comprehensive pharmacologic therapy for treatment of a dysfunction
Title: United States Patent: 7,547,723 Inventors: Hinz; Martin C.(Duluth, MN) Appl. No.: 11/157,198 Filed: June 20, 2005 Web Seminars-- Pharm/Biotech/etc. The comprehensive pharmacologic therapy for treatment of obesity is a procedure...
|
|
|
Research and Markets: Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion to For
- Research and Markets (http://www.researchandmarkets.com/research/841a94/forecast_insight) has announced the addition of the 'Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion' report to their offering....
|
|
|
Research and Markets: Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion to For
Research and Markets ( www.researchandmarkets.com/research/841a94/forecast_insight : ) has announced the addition of the ' Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion : ' report to their offering....
|
|
|
Research and Markets: Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion to For
Research and Markets (http://www.researchandmarkets.com/research/841a94/forecast_insight) has announced the addition of the 'Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion' report to their offering.
|
|
|
Research and Markets: Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion to For
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/841a94/forecast_insight) has announced the addition of the '' report to their offering.Until regulatory hurdles in the EU are overcome, the US...
|
|
|
Research and Markets: Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion to For
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/841a94/forecast_insight) has announced the addition of the '' report to their offering.Until regulatory hurdles in the EU are overcome, the US...
|
|
|
Research and Markets: Forecast Insight: Fibromyalgia - Regulatory Caution Threatens EU Market Expansion to For
Research and Markets: to Forecasted $2.5 Billion by 2018 DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/841a94/forecast_insight) has announced the addition of the '' report to their offering.
|
|
|
Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia
Claims database analysis to describe prescription and medical use in pts with newly diagnosed and established fibromyalgia Privately insured pts with 2+ myalgia/myositis claims (1999-2005) were categorized as newly diagnosed or...
|
|
|
NIMS Announces FDA Grants Approval to Expand Exer-Rest Indications to Include Reduction of Morning Stiffness
- (NewsRx.com) -- Non-Invasive Monitoring Systems, Inc.[NIMS] (OTCBB:NIMU) announced that the FDA has cleared NIMS to market the Exer-Rest, a Class I (exempt) medical device, with the expanded indication to reduce morning stiffness.
|
|
|
Clinical Trials Update: June 30, 2009
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch and ClinicalConnection.com: Chronic Obstructive Pulmonary Disease (COPD) If you are at least 40 and a current or former smoker with chronic obstructive...
|
|
|
Biotech Calendar: Key Clinical Trial Dates
I'm back with the third list of clinical trials covering experimental drugs currently undergoing testing in phase II and phase III studies by drug and biotech companies.This installment, like the previous two, covers clinical trials with...
|
|
|
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia M
Preliminary top-line results of second Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study PALO ALTO, Calif., and...
|
|
|
Fibromyalgia: Milnacipran: A New Treatment Option for Fibromyalgia
Print Save in My Library Free Abstract Mease PJ - On January 14, 2009 the Food and Drug Administration approved the use of SavellaTM (milnacipran) for the treatment of fibromyalgia.This third approved drug offers health care...
|
|
|
Cash-Strapped Jazz Gets Stock Bump From Data On Fibromyalgia Candidate
_ Cash-Strapped Jazz Gets Stock Bump From Data On Fibromyalgia Candidate.
|
|
|
Peripheral mechanism of muscle pain: An update
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Current Anaesthesia and Critical Care, 06/26/09 Print Save in My Library Free Abstract Mizumura K - This review introduces recent results obtained from...
|
|
|
Jazz Pharmaceuticals/UCB: fibromyalgia beckons for narcolepsy drug
(Datamonitor via COMTEX) -- JAZZ | Quote | Chart | News | PowerRating -- New positive top-line results from a second Phase III clinical trial of sodium oxybate in fibromyalgia show that the drug is on track for FDA approval.As such,...
|
|
|
Jazz Pharma's second Phase III fibromyalgia trial meets primary endpoint
(Datamonitor via COMTEX) -- JAZZ | Quote | Chart | News | PowerRating -- Jazz Pharmaceuticals, a specialty pharmaceutical company, and UCB, a biopharmaceutical company, have reported positive preliminary topline results from the second of...
|
|
|
Jazz Pharmaceuticals shares fall as Barclay's analyst downgrades on stock value, debt concern
NEW YORK (AP) - Shares of Jazz Pharmaceuticals Inc.fell Friday as a Barclay's Capital analyst downgraded the stock based on its value and the company's debt. The stock fell 25 cents, or 5.6 percent, to $4.23 in midday trading. Shares...
|
